278 related articles for article (PubMed ID: 15802532)
21. Function of the Fanconi anemia pathway in Fanconi anemia complementation group F and D1 cells.
Siddique MA; Nakanishi K; Taniguchi T; Grompe M; D'Andrea AD
Exp Hematol; 2001 Dec; 29(12):1448-55. PubMed ID: 11750104
[TBL] [Abstract][Full Text] [Related]
22. HSP70 inhibition reverses cell adhesion mediated and acquired drug resistance in multiple myeloma.
Nimmanapalli R; Gerbino E; Dalton WS; Gandhi V; Alsina M
Br J Haematol; 2008 Aug; 142(4):551-61. PubMed ID: 18503584
[TBL] [Abstract][Full Text] [Related]
23. Current knowledge on the pathophysiology of Fanconi anemia: from genes to phenotypes.
Yamashita T; Nakahata T
Int J Hematol; 2001 Jul; 74(1):33-41. PubMed ID: 11530803
[TBL] [Abstract][Full Text] [Related]
24. Multiple repair pathways mediate tolerance to chemotherapeutic cross-linking agents in vertebrate cells.
Nojima K; Hochegger H; Saberi A; Fukushima T; Kikuchi K; Yoshimura M; Orelli BJ; Bishop DK; Hirano S; Ohzeki M; Ishiai M; Yamamoto K; Takata M; Arakawa H; Buerstedde JM; Yamazoe M; Kawamoto T; Araki K; Takahashi JA; Hashimoto N; Takeda S; Sonoda E
Cancer Res; 2005 Dec; 65(24):11704-11. PubMed ID: 16357182
[TBL] [Abstract][Full Text] [Related]
25. Curcumin reverses cisplatin resistance in cisplatin-resistant lung caner cells by inhibiting FA/BRCA pathway.
Chen P; Li J; Jiang HG; Lan T; Chen YC
Tumour Biol; 2015 May; 36(5):3591-9. PubMed ID: 25542235
[TBL] [Abstract][Full Text] [Related]
26. PARP Inhibition Synergizes with Melphalan but Does not Reverse Resistance Completely.
Patel PR; Senyuk V; Sweiss K; Calip GS; Pan D; Rodriguez N; Oh A; Mahmud N; Rondelli D
Biol Blood Marrow Transplant; 2020 Jul; 26(7):1273-1279. PubMed ID: 32194286
[TBL] [Abstract][Full Text] [Related]
27. The Fanconi anemia protein FANCF forms a nuclear complex with FANCA, FANCC and FANCG.
de Winter JP; van der Weel L; de Groot J; Stone S; Waisfisz Q; Arwert F; Scheper RJ; Kruyt FA; Hoatlin ME; Joenje H
Hum Mol Genet; 2000 Nov; 9(18):2665-74. PubMed ID: 11063725
[TBL] [Abstract][Full Text] [Related]
28. c-MYC deregulation is involved in melphalan resistance of multiple myeloma: role of PDGF-BB.
Greco C; D'Agnano I; Vitelli G; Vona R; Marino M; Mottolese M; Zuppi C; Capoluongo E; Ameglio F
Int J Immunopathol Pharmacol; 2006; 19(1):67-79. PubMed ID: 16569345
[TBL] [Abstract][Full Text] [Related]
29. Bcl-2 overexpression is associated with resistance to dexamethasone, but not melphalan, in multiple myeloma cells.
Gazitt Y; Fey V; Thomas C; Alvarez R
Int J Oncol; 1998 Aug; 13(2):397-405. PubMed ID: 9664139
[TBL] [Abstract][Full Text] [Related]
30. The Fanconi Anemia/BRCA signaling pathway: disruption in cisplatin-sensitive ovarian cancers.
D'Andrea AD
Cell Cycle; 2003; 2(4):290-2. PubMed ID: 12851475
[TBL] [Abstract][Full Text] [Related]
31. Involvement of Fanconi anemia genes FANCD2 and FANCF in the molecular basis of drug resistance in leukemia.
Yao C; Du W; Chen H; Xiao S; Huang L; Chen FP
Mol Med Rep; 2015 Jun; 11(6):4605-10. PubMed ID: 25647473
[TBL] [Abstract][Full Text] [Related]
32. Didox, a ribonucleotide reductase inhibitor, induces apoptosis and inhibits DNA repair in multiple myeloma cells.
Raje N; Kumar S; Hideshima T; Ishitsuka K; Yasui H; Chhetri S; Vallet S; Vonescu E; Shiraishi N; Kiziltepe T; Elford HL; Munshi NC; Anderson KC
Br J Haematol; 2006 Oct; 135(1):52-61. PubMed ID: 16925573
[TBL] [Abstract][Full Text] [Related]
33. The Fanconi anemia pathway sensitizes to DNA alkylating agents by inducing JNK-p53-dependent mitochondrial apoptosis in breast cancer cells.
Zhao L; Li Y; He M; Song Z; Lin S; Yu Z; Bai X; Wang E; Wei M
Int J Oncol; 2014 Jul; 45(1):129-38. PubMed ID: 24789349
[TBL] [Abstract][Full Text] [Related]
34. The FANC/BRCA Pathway Releases Replication Blockades by Eliminating DNA Interstrand Cross-Links.
Renaudin X; Rosselli F
Genes (Basel); 2020 May; 11(5):. PubMed ID: 32466131
[TBL] [Abstract][Full Text] [Related]
35. Down-regulation of CD98 in melphalan-resistant myeloma cells with reduced drug uptake.
Harada N; Nagasaki A; Hata H; Matsuzaki H; Matsuno F; Mitsuya H
Acta Haematol; 2000; 103(3):144-51. PubMed ID: 10940652
[TBL] [Abstract][Full Text] [Related]
36. RNA interferences targeting the Fanconi anemia/BRCA pathway upstream genes reverse cisplatin resistance in drug-resistant lung cancer cells.
Dai CH; Li J; Chen P; Jiang HG; Wu M; Chen YC
J Biomed Sci; 2015 Sep; 22(1):77. PubMed ID: 26385482
[TBL] [Abstract][Full Text] [Related]
37. Genetic inactivation of the Fanconi anemia gene FANCC identified in the hepatocellular carcinoma cell line HuH-7 confers sensitivity towards DNA-interstrand crosslinking agents.
Palagyi A; Neveling K; Plinninger U; Ziesch A; Targosz BS; Denk GU; Ochs S; Rizzani A; Meier D; Thasler WE; Hanenberg H; De Toni EN; Bassermann F; Schäfer C; Göke B; Schindler D; Gallmeier E
Mol Cancer; 2010 May; 9():127. PubMed ID: 20509860
[TBL] [Abstract][Full Text] [Related]
38. Modulation of cell metabolic pathways and oxidative stress signaling contribute to acquired melphalan resistance in multiple myeloma cells.
Zub KA; Sousa MM; Sarno A; Sharma A; Demirovic A; Rao S; Young C; Aas PA; Ericsson I; Sundan A; Jensen ON; Slupphaug G
PLoS One; 2015; 10(3):e0119857. PubMed ID: 25769101
[TBL] [Abstract][Full Text] [Related]
39. DNA interstrand cross-link repair: understanding role of Fanconi anemia pathway and therapeutic implications.
Shukla P; Solanki A; Ghosh K; Vundinti BR
Eur J Haematol; 2013 Nov; 91(5):381-93. PubMed ID: 23859405
[TBL] [Abstract][Full Text] [Related]
40. Interaction of melphalan and dexamethasone in a human myeloma cell line.
Fernberg JO; Lewensohn R; Skog S
Anticancer Drugs; 1991 Dec; 2(6):565-70. PubMed ID: 1806033
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
